Fruquintinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), CIPM (Spain) and G-BA (Germany), among others, recommended or restricted fruquintinib, while DMC (Denmark) and HAS (France) did not recommend it.
The record spans 2.2 years, opening at PBAC (Australia) in 2024 and running to 3 Sep 2026.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 14 of 14 records date from 2023 or later.
4 distinct indication wordings are recorded for fruquintinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess fruquintinib, in 2024; HIRA (South Korea) did not open a file until 3 Sep 2026 — a moderate spread of 2.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 14 dated records fall in 2025 alone.
PBAC (Australia) is the only agency to have returned to fruquintinib, recording 2 separate entries.
fruquintinib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for fruquintinib reads 8 recommended, 2 not recommended, 1 appraised and 1 deferred to NICE, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 27 May 2026 | Voksne patienter med metastatisk kolorektalkræft (mCRC), som tidligere er blevet behandlet med tilgængelige standardbeha… | Ikke anbefalet | source |
| TLV (Sweden) | 22 Dec 2025 | Fruzaqla ingår i högkostnadsskyddet | general subsidy | source |
| SMC (Scotland) | 13 Oct 2025 | For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxali… | accepted | source |
| NICE (England) | 23 Jul 2025 | NICE TA1079 | published appraisal | source |
| AWMSG (Wales) | 25 Jun 2025 | For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with avail… | excluded, NICE appraised | source |
9 further decisions for fruquintinib, across 8 agencies, are not shown here. They include the most recent record on file, 3 Sep 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- cetuximab — divergent outcome (recommended vs not recommended) on a shared indication
- trifluridine — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
Coverage: 14 decisions for fruquintinib from 13 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.